Could PD-L1 positive cell density be a prognostic biomarker?

The hunt is on for ways to predict response to immune checkpoint inhibitors in NSCLC
Medicom Staff writer
microscope

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

French researchers are suggesting that measuring the density of positive programmed death ligand 1 cells in a biopsy might help predict response to immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC).